U.S. Medical Equipment Stock News

NYSE:SFL
NYSE:SFLOil and Gas

Should SFL’s (SFL) Higher Dividend and Extended Buyback Plan Require Action From Investors?

SFL Corporation Ltd. has already reported first-quarter 2026 results, posting revenue of US$174.48 million, net income of US$26.08 million, basic earnings per share of US$0.20, and declaring a quarterly cash dividend of US$0.22 per share payable around June 22, 2026, while extending its share buyback plan to June 2028. Together, the higher cash dividend and extended buyback plan point to management’s confidence in SFL’s cash-generating capacity and its commitment to ongoing shareholder...
NYSE:KIM
NYSE:KIMRetail REITs

Is Alleged Lease Fraud Around Target Redevelopment Altering The Investment Case For Kimco Realty (KIM)?

In May 2026, Drip Coffee sued Kimco Realty in a Florida state court, alleging the REIT fraudulently induced multi‑year leases while concealing plans to demolish over 100,000 square feet of a shopping center to accommodate a Target redevelopment. The case raises questions about Kimco’s tenant‑relations practices and disclosure around redevelopment projects, issues that sit at the core of its open‑air shopping center business model. We’ll now examine how allegations that Kimco concealed...
NasdaqGS:BPOP
NasdaqGS:BPOPBanks

The Bull Case For Popular (BPOP) Could Change Following Governance Amendments And Sustained Dividend Payouts – Learn Why

Earlier in May 2026, Popular, Inc. approved amendments to its Restated Certificate of Incorporation in Puerto Rico, including updated indemnification and director election provisions, while also declaring a quarterly cash dividend of US$0.75 per common share payable on July 1, 2026. These governance changes, paired with an ongoing performance-focused culture and heightened options-market activity, point to a company tightening internal accountability while attracting fresh investor...
NYSE:BNT
NYSE:BNTInsurance

A Look At Brookfield Wealth Solutions (BNT) Valuation After Weaker First Quarter Revenue And Wider Net Loss

Brookfield Wealth Solutions (BNT) is back in focus after first quarter results showed revenue of US$1,656 million compared with US$2,618 million a year earlier, alongside a net loss that widened from US$326 million to US$609 million. See our latest analysis for Brookfield Wealth Solutions. At a share price of US$45.35, the stock has seen a 7 day share price return that declined 4.6% and a year to date share price return that declined 2.9%. By contrast, the 1 year total shareholder return of...
NasdaqGM:GCT
NasdaqGM:GCTRetail Distributors

Is It Too Late To Consider GigaCloud Technology (GCT) After A 106% One Year Surge?

Wondering if GigaCloud Technology at around US$38.55 is still offering value, or if the big gains are already behind it? This article breaks down what the current price might be implying about the stock. The stock has risen 4.0% over the past week, even though it is down 18.7% over the last 30 days and slightly down 0.5% year to date, while still showing a very large 1 year return of 105.9% and an even larger 3 year return. Recent coverage has focused on GigaCloud Technology as a fast...
NYSE:PSA
NYSE:PSASpecialized REITs

Is Public Storage (PSA) Offering Value After Its Recent Share Price Strength?

Wondering if Public Storage at about US$304.99 a share offers fair value or if the price is out of line with the fundamentals? This article breaks down what the market is currently implying. The stock has delivered a 0.6% return over the last week, is down 1.1% over the past month, and is up 18.0% year to date, with a 7.5% return over the past year that sits alongside 21.8% and 35.3% returns over the past 3 and 5 years. Recent coverage has focused on Public Storage as a large self storage...
NYSE:TMO
NYSE:TMOLife Sciences

Thermo Fisher’s New Sweden Lab Deepens Role In Global Drug Development

Thermo Fisher Scientific (NYSE:TMO) has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden. The facility is designed to support pharmaceutical and biotechnology companies across all stages of drug development. The lab is connected to Thermo Fisher Scientific's global network of drug development services. Thermo Fisher Scientific, trading at around $449.37, sits at the crossroads of tools, services, and outsourced support that many drug developers rely on. The stock is...
NasdaqGM:RLAY
NasdaqGM:RLAYBiotechs

Relay Therapeutics (RLAY) Is Up 6.9% After Zovegalisib Phase 2 Data And Equity Raise - Has The Bull Case Changed?

Earlier in May 2026, Relay Therapeutics completed a US$275,000,004 follow-on equity offering at US$12 per share after releasing initial Phase 2 ReInspire data showing zovegalisib achieved a 60% volumetric response rate and broad symptom improvement in PIK3CA‑driven vascular anomalies with a safety profile supportive of chronic dosing. An interesting angle is that zovegalisib is being advanced simultaneously in rare vascular anomalies and in an ongoing Phase 3 program for metastatic breast...
NasdaqGM:HPK
NasdaqGM:HPKOil and Gas

A Look At HighPeak Energy (HPK) Valuation As Oil Prices Break Above $100 On Geopolitical Tensions

Oil price shock and HighPeak Energy's stock reaction HighPeak Energy (HPK) moved higher after crude oil prices climbed above $100 a barrel, as mounting geopolitical tensions and potential Strait of Hormuz disruptions fed through to oil linked equities and heightened day to day volatility. See our latest analysis for HighPeak Energy. Beyond the latest oil price shock, HighPeak Energy’s share price has shown strong short term momentum, with a 30 day share price return of 20.46% and a year to...
NYSE:RMD
NYSE:RMDMedical Equipment

How ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem

On 19 May 2026, ResMed and Oura announced a partnership that connects Oura Ring Gen3 and Ring 4 members in the U.S. to ResMed’s sleep education tools, assessments, and options to link with independent healthcare providers. This collaboration uniquely bridges consumer wearable sleep data with clinical sleep resources, aiming to help address undiagnosed conditions such as obstructive sleep apnea. Next, we’ll examine how integrating Oura’s consumer wearables data with ResMed’s clinical sleep...
NYSE:MTDR
NYSE:MTDROil and Gas

Matador Resources Expands Delaware Basin Acreage And Extends Drilling Runway

Matador Resources (NYSE:MTDR) has agreed to acquire over 5,000 net undeveloped acres in the Delaware Basin. The transaction expands the company’s core acreage position and adds to its future drilling inventory. The newly acquired acreage is described as high quality and directly increases Matador’s reserve base. For investors tracking NYSE:MTDR, this acreage deal comes with the stock around $56.09 and a return of 29.4% year to date and 32.6% over the past year. Over a 5-year period, the...
NYSE:CUBE
NYSE:CUBESpecialized REITs

How Investors Are Reacting To CubeSmart (CUBE) Dividend Hike, Earnings Beat And NYC Recovery Update

Earlier this week, CubeSmart’s board declared a past quarterly dividend of US$0.53 per share for the period ended June 30, 2026, payable on July 15 to shareholders of record as of July 1. Alongside the dividend, investors reacted to CubeSmart’s Q1 2026 earnings beat and upbeat New York City operating update, which highlighted a strong recovery in same-store revenue and net rentals. We’ll now examine how the Q1 earnings beat and improving New York City fundamentals may reshape CubeSmart’s...
NYSE:BMI
NYSE:BMIElectronic

The Bull Case For Badger Meter (BMI) Could Change Following Q1 Sales Drop And Fraud Probes – Learn Why

Earlier in 2026, Badger Meter disclosed a year-over-year 9% first-quarter sales decline, especially in utility water products, prompting law firms to investigate potential securities violations tied to its communications on demand and growth. At the same time, the company pressed ahead with its 2026 Investor Day webcast to outline its smart water strategy and long-term framework, underscoring a gap between its growth messaging and recent operational headwinds. Against this backdrop of weaker...
NasdaqGS:LEGN
NasdaqGS:LEGNBiotechs

A Look At Legend Biotech (LEGN) Valuation After Its Strong Q1 2026 Revenue And Narrower Net Loss

Legend Biotech (LEGN) drew fresh attention after reporting first quarter 2026 results, with revenue of US$305.1 million, a narrower net loss of US$54.3 million, and reduced loss per share versus a year earlier. See our latest analysis for Legend Biotech. The quarterly update comes after a sharp 54.47% 90 day share price return and a 30.13% year to date share price gain, contrasting with a 3.65% decline in 1 year total shareholder return and a 55.77% decline over 3 years. This suggests recent...
NasdaqGS:ADUS
NasdaqGS:ADUSHealthcare

A Look At Addus HomeCare (ADUS) Valuation After Recent Share Price Weakness

Addus HomeCare (ADUS) has drawn investor attention after recent trading left the stock around $93.26, with performance mixed over the past year and fundamentals that highlight its position in US home-based care services. See our latest analysis for Addus HomeCare. The recent move to around $93.26 comes after a modest 7 day share price return of 0.92%. However, the 90 day share price return is down 19.24%, and the 1 year total shareholder return is down 16.38%. This points to fading momentum...
NasdaqGS:CSGS
NasdaqGS:CSGSProfessional Services

Has The Market Gone Too Far With CSG Systems International (CSGS) After Strong Multi‑Year Gains?

If you are wondering whether CSG Systems International at US$80.69 is offering good value or stretching expectations, the starting point is understanding how the current price lines up against a few core valuation checks. The stock has returned 0.4% over the past week, 0.4% over the last month, 5.1% year to date, 25.2% over 1 year, 74.4% over 3 years and 101.0% over 5 years, which may prompt you to question whether the current valuation still looks reasonable. Recent headlines around CSG...
NYSE:KRC
NYSE:KRCOffice REITs

Kilroy Realty (KRC) Valuation Check After Mixed Short Term Gains And Year To Date Share Price Decline

Recent performance snapshot Kilroy Realty (KRC) has drawn investor attention after a mixed return profile, with the stock up over the past month and past 3 months, but down year to date. Over the past month, Kilroy Realty has gained about 7%, adding to a roughly 6% rise over the past 3 months, while the stock remains about 10% lower year to date. See our latest analysis for Kilroy Realty. At a share price of $34.14, Kilroy Realty’s recent 7.3% 1 month share price return contrasts with a year...
NasdaqGS:WSBC
NasdaqGS:WSBCBanks

A Look At WesBanco (WSBC) Valuation After Expanded Buyback And Fresh Dividend Declarations

WesBanco (WSBC) has given investors fresh news to consider by expanding its stock repurchase authorization by 4.0 million shares and declaring quarterly dividends for both common and preferred shareholders. See our latest analysis for WesBanco. At a share price of $34.62, WesBanco has seen short term momentum soften, with a 30 day share price return of 3.11% and a 90 day decline of 6.05%. At the same time, a 1 year total shareholder return of 18.73% and a 3 year total shareholder return of...
NYSE:AEM
NYSE:AEMMetals and Mining

Agnico Eagle Mines (NYSE:AEM) Valuation Check After Recent Share Price Pullback

Recent performance snapshot Agnico Eagle Mines (NYSE:AEM) has drawn investor attention after a period in which the stock fell about 12% over the past month and about 22% over the past 3 months, against a backdrop of mixed return signals. See our latest analysis for Agnico Eagle Mines. The recent slide, including a 7 day share price return of down 7.74% and a 3 month share price return of down 22.13%, contrasts sharply with Agnico Eagle Mines' 1 year total shareholder return of 56.72%. This...
NasdaqGS:NUVL
NasdaqGS:NUVLBiotechs

Nuvalent ASCO 2026 Data Puts Neladalkib And Zidesamtinib In Focus

Nuvalent plans to present pivotal clinical trial data at the 2026 ASCO Annual Meeting. The presentations include neladalkib data in ALK-positive NSCLC that supported a recent FDA NDA submission and an ongoing Phase 3 trial. The company will also share the first clinical look at zidesamtinib in ROS1-positive solid tumors, including early response data. Nuvalent (NasdaqGS:NUVL) is drawing attention ahead of ASCO 2026 as it prepares to showcase data that underpin a recent FDA NDA filing for...
NYSE:TPR
NYSE:TPRLuxury

Tapestry (TPR) Valuation Check As Patent Win For Mira Highlights In House AI Ambitions

Tapestry (TPR) has just secured a U.S. patent for Mira, its in house AI platform built to connect data across the business and support faster decisions around inventory, assortments and consumer trends. See our latest analysis for Tapestry. The patent news lands as Tapestry’s share price, now at US$139.11, reflects mixed momentum, with a 7 day share price return of 6.81% and a 30 day return that fell 7.57%, while the 1 year total shareholder return of 78.66% points to a strong longer term...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Assessing Halozyme Therapeutics (HALO) Valuation After Recent Flat Share Price And Strong Longer Term Returns

Why Halozyme Therapeutics (HALO) Is Drawing Investor Attention Now Halozyme Therapeutics (HALO) is back on investors’ radar after a period of mixed share performance, with the stock roughly flat over the past month but lower over the past 3 months. See our latest analysis for Halozyme Therapeutics. At around US$68.52, Halozyme’s recent share price moves have been relatively muted, yet the 1 year total shareholder return of 27.48% and 3 year total shareholder return of 106.76% point to longer...
NasdaqGS:MANH
NasdaqGS:MANHSoftware

Assessing Manhattan Associates (MANH) Valuation After A Mixed Share Price And Earnings Outlook

Stock performance snapshot Manhattan Associates (MANH) has been drawing attention after a mixed run in recent months, with the stock down about 20% year to date and roughly 28% over the past year. Short term performance looks different. The share price eased around 1.8% in the latest session but rose about 4.3% over the past week and has held close to flat over the past month. Over longer periods the picture has been weaker, with total returns declining about 23% over three years and roughly...